<div id="readability-page-1">Procept Biorobotics Corp. (NASDAQ:PRCT) is one of the most promising mid-cap healthcare stocks under $50. On December 12, UBS analyst Danielle Antalffy initiated coverage with a bullish rating on Procept Biorobotics Corp. (NASDAQ:PRCT). She rated the stock as a Buy and estimated a target price of $62. This leads to an upside potential of over […]</div>

PRCT

<p>瑞银分析师 Danielle Antalffy 对 Procept Biorobotics Corp.（纳斯达克代码：PRCT）启动了覆盖，给予 “买入” 评级，目标价为 62 美元，显示出显著的上涨潜力</p>

乐观的增长预测使分析师对 PROCEPT BioRobotics（PRCT）充满信心